Moving gemcitabine/nab-paclitaxel to every-other-week dosing decreases infusion visits and may lessen cumulative toxicity, ...
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable ...
The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights. Adjuvant platinum-based chemotherapy plus paclitaxel ...
Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized ...
The ROSELLA trial showed relacorilant plus nab-paclitaxel improved progression-free survival in platinum-resistant ovarian cancer patients. Relacorilant reduced disease progression risk by 30% and ...
Please provide your email address to receive an email when new articles are posted on . Seventeen patients received albumin-bound paclitaxel infusion every 3 weeks for up to six cycles.
University of Arizona researchers devised a new method to deliver cancer chemotherapy drugs to pancreatic and breast cancer tumors more effectively and with less damage to healthy tissues than ...
While many of the women in the responding patient population likely achieved an improvement in symptoms and overall survival, most of the responses were unfortunately (but certainly not surprisingly) ...
The widely used chemotherapy drug Taxol does not work for the most common form of breast cancer and helps far fewer patients than has been believed, surprising new research suggests. If further study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results